Site Map

Products
	Trima Accel® Collection System
	How it Works
	Automation Benefits
	Accessories
	User Materials
	Spectra Optia® Apheresis System
	How it Works
	Additional Information
	Tubing Sets & Accessories
	COBE® Spectra Apheresis System
	How it Works
	What is Therapeutic Apheresis?
	What is Cell Therapy?
	Accessories
	Vista® Information System
	How it Works
	Regulatory Compliance
	Apheresis Management
	Elutra® Cell Separation System
	How it Works
	Monocyte Enrichment
	Elutra Publications
	Accessories
	Atreus® Whole Blood Processing System
	How it Works
	OrbiSac® System
	How it Works
	Atreus / OrbiSac Synergy
	Mirasol® Pathogen Reduction Technology
	How it Works
	Mirasol Safety and Effectiveness
	COBE® 2991 Cell Processor
	How it Works
	Accessories
	Accessories & Supplies
Blood Center
	Donor Recruitment and Conversion
	Donor Conversion Program
	Donor Conversion Materials
	Collections Progression
	Collections History
	Automated Collections
	Trima Mobile Collections
	Trima Mobiles on the Road
	Trima Mobile Collection Guide
	Resources
	Centers of Excellence
	Component Processing Lab
	Regulatory Q/A
	Information Technology
Therapeutic Apheresis & Cell Therapy Systems
	Conditions Treated with Therapeutic Apheresis
	Conditions Treated with Cell Therapy
	Therapeutic Apheresis Procedures
	Cell Therapy Procedures
Blood Products
	Platelets
	Single-Donor Platelets
	Plasma
	Red Blood Cells
	Buffy Coat Platelets
	Whole Blood
	Component Safety
	Bacterial Testing
	Pathogen Reduction Technology
Support Center
	SOPs
	IFUs
	Diagrams
	Operator Manuals
	Workbooks
	Support Materials
	ISBT Conversion
	Brochures
	White Papers
	Scientific Literature
	Congress Presentations
	Tools
	Calculation Tools
	Links
	Educational Events
	eSessions
		eSessions Presentations
	Successions 2
		Program Details
	Certificates and Customer Letters
	Customer Letters
	ACD-A and AS-3
	Contact Us
About CaridianBCT
	Events
	AABB members contribute over $10,000 to National Blood Foundation
	Beauprez visits Gambro campus where federal grants are at work
	Navigant Biotechnologies awarded additional USD 2 M Department of Defense research funding
	Positive results from clinical trial of platelets treated with Gambro's Mirasol™ Pathogen Reduction Technology
	Gambro BCT's blood collection system approved by Japanese Red Cross
	Navigant Biotechnologies Awarded $2M Department of Defense Research Funding
	Gambro BCT's platelet technology cleared by the US Food and Drug Administration for seven day storage
	US FDA clears Gambro BCT’s software for interface with blood center information systems
	Navigant Biotechnologies launches website
	Gambro BCT and MAK-SYSTEM collaborate to help blood centers optimize automated blood collection
	Teresa Ayers appointed President and CEO of Navigant Biotechnologies, Inc., Gambro's subsidiary for Pathogen Reduction Technology
	Gambro announces successful research results for inactivation of West Nile Virus in donated blood
	Gambro establishes separate company to capture full potential of pathogen reduction technology
	Gambro BCT agreement with American Red Cross to supply Trima Automated Blood Collection Technologies
	Gambro announces research results for inactivation of malaria in donated blood
	Milestone achievement in virus inactivation technology by Gambro to be used in new artificial blood substitute
	Gambro BCT receives FDA approval for new red blood cell storage solution
	Gambro BCT's Vista™ Software Receives FDA Market Clearance
	Gambro BCT receives FDA approval for new anticoagulant solution
	Gambro BCT receives FDA clearance for new tubing sets with an integrated red blood cell leukoreduction filter
	Hemocentro de São Paulo in Brazil adopts Gambro BCT's Trima^® Automated Blood Collection System
	Blood Systems Inc. adopts Gambro's Trima System Technology
	Dendreon Corporation and Gambro team up for US cell collection network for commercialization of cancer vaccine therapy
	Excellent marks from AABB Users' Conference attendees
	Gambro's Pathogen Eradication Technology (PET) will be used in the production of Sangart's blood substitute product
	Gambro awarded US patent for its unique process of inactivation of pathogens in blood components
	Gambro acquires the assets owned by Sanguistech and increases its competitiveness in global blood component technology
	Gambro BCT announces research partnership with Walter Reed Army Institute of Research for application of Pathogen Eradication Technology to malaria
	Kevin Simpson new Vice President, Gambro BCT and General Manager of its Pathogen Eradication Technology Project
	Translation from an entry on the Swedish Reuters screen Monday, January 15, 2001
	Gambro BCT announces red blood cell Pathogen Eradication Technology (PET) performance
	Gambro BCT Enhances Pathogen Eradication Technology (PET) Performance
Careers
	About Our Culture
	Benefits & Services
	FAQs
	Help Save Lives - Join Our Assembly Team